PATRICIA DEHOF: Open Payments
NPI 1376611400 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$450 in 20 payments from 12 companies in 2025. Trend: 2023 $442 · 2024 $145 · 2025 $450
Food & beverage: $450
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $79 |
| MAYNE PHARMA COMMERCIAL LLC | 3 | $66 |
| Sumitomo Pharma America, Inc. | 3 | $61 |
| Daiichi Sankyo Inc. | 2 | $57 |
| SHIELD THERAPEUTICS INC | 2 | $54 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Amgen Inc. | 1 | $21 |
| Sage Therapeutics, LLC | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| CooperSurgical, Inc. | 1 | $18 |
Products named: Veozah, INJECTAFER, ACCRUFER, GEMTESA, GARDASIL 9, EVENITY, MYFEMBREE, ZURZUVAE.
Industry payments across MD — which companies pay providers there.
